Company profile
AXOGEN, INC.
NASDAQ:AXGNBiotechnology: Electromedical & Electrotherapeutic Apparatus
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AVANCE NERVE GRAFT | approved | $69.7MQ2 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07657182 | phase4 | recruiting | 2026-06-11 | 2030-12-05 | Axogen Corporation | A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction |
| NCT01809002 | phase3 | completed | 2015-06-01 | 2021-08-30 | Axogen Corporation | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125816 | 2025-12-03 | BLA | AXOGEN CORPORATION | |||||
Loading… | ||||||||